• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

    9/17/24 11:22:47 AM ET
    $AZN
    $BLTE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    September 24 Agenda (US Eastern Standard Time):

    • 8:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 8:30 AM: Lotus Technology Inc (NASDAQ:LOT)
    • 9:00 AM: HUTCHMED (China) Limited ((AIM: HCM, NASDAQ:HCM, and HKEX:13))
    • 9:30 AM: iHuman Inc. (NYSE:IH)
    • 10:00 AM: Marks and Spencer ((LSE: MKS, OTC:MAKSY)
    • 10:30 AM: SSE plc ((LSE: SSE, OTC:SSEZY)
    • 11:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 11:30 AM: AstraZeneca plc ((LSE: AZN, NASDAQ:AZN)

    September 25 Agenda (US Eastern Standard Time):

    • 8:00 AM: Yiren Digital Ltd (NYSE:YRD)
    • 8:30 AM: KPN ((Euronext Amsterdam: KPN, OTC:KKPNY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM: Carrefour S.A. (PARIS:CA, OTC:CRRFY)
    • 10:00 AM: EDP Group ((Euronext Lisbon: EDP, OTC:EDPFY)
    • 10:30 AM: Repsol S.A ((BMAD: REP, OTC:REPYY)
    • 11:00 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:30 AM: DSM-Firmenich AG ((DSFIR:AEX, OTC:DSFIY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $BLTE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    More analyst ratings

    $AZN
    $BLTE
    $HCM
    $IH
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    3/27/26 8:04:57 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Viomi Technology Co. Ltd

    6-K - Viomi Technology Co., Ltd (0001742770) (Filer)

    3/25/26 7:00:14 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    3/23/26 6:07:14 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

    First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozorakimab was generally well tolerated with a fa

    3/27/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") in China. The first patient received the first dose on March 20, 2026. DLBCL is the most common form of aggressive non-Hodgkin lymphoma ("NHL") worldwide, accounting for approximately 40% of all NHL cases in China.1  In 2022, approximately 81,000 new cases of NHL are estimated to have been diagnosed in China

    3/22/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yiren Digital Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    BEIJING, March 19, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced its unaudited financial results for the fourth quarter and 2025 fiscal year ended December 31, 2025. Fourth Quarter and Fiscal Year 2025 Operational HighlightsCredit Solution Business (formerly known as Financial Services Business)Total loans facilitated in the fourth quarter of 2025 was RMB12.0 billion (US$1.7 billion), representing a decrease of 40% compared to RMB20.2 billion in the third quarter of 2025 and a decrease of 22

    3/19/26 7:00:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    $AZN
    $BLTE
    $HCM
    $IH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Li Hao

    3 - Yiren Digital Ltd. (0001631761) (Issuer)

    3/26/26 4:02:54 PM ET
    $YRD
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Feng Qingfeng

    3 - Lotus Technology Inc. (0001962746) (Issuer)

    3/26/26 6:33:22 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form 3 filed by new insider Sharma Mani

    3 - ASTRAZENECA PLC (0000901832) (Issuer)

    3/19/26 7:51:36 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    View All

    Yiren Digital Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    BEIJING, March 19, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced its unaudited financial results for the fourth quarter and 2025 fiscal year ended December 31, 2025. Fourth Quarter and Fiscal Year 2025 Operational HighlightsCredit Solution Business (formerly known as Financial Services Business)Total loans facilitated in the fourth quarter of 2025 was RMB12.0 billion (US$1.7 billion), representing a decrease of 40% compared to RMB20.2 billion in the third quarter of 2025 and a decrease of 22

    3/19/26 7:00:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Yiren Digital to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    BEIJING, March 11, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, announced that it plans to release its unaudited financial results for the fourth quarter and full year ended December 31, 2025 before U.S. market opens on Thursday, March 19, 2026. Yiren Digital's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on March 19, 2026 (or 8:00 p.m. Beijing/Hong Kong Time on March 19, 2026).Participants who wish to join the call should register online in advance of the conference at:

    3/11/26 5:00:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Viomi Technology Co., Ltd to Report Second Half and Full Year 2025 Financial Results on Wednesday, March 25, 2026

    GUANGZHOU, China, March 02, 2026 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced that it will report its unaudited financial results for the second half and the full year ended December 31, 2025 on Wednesday, March 25, 2026, before the open of the U.S. markets. The Company's management will host an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 25, 2026 (8:00 P.M. Beijing/Hong Kong time on March 25, 2026). For participants who wish to join the conference using dial-in numbers, please complete online registration using the link provided below prior to t

    3/2/26 4:00:00 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    $AZN
    $BLTE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    View All

    LOTUS Appoints Piano Master Lang Lang as Friend of the Brand

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today updated that LOTUS announced world-renowned pianist Lang Lang as its Friend of the Brand, marking a new partnership built on a shared pursuit of precision, performance, and excellence. Recognized globally for his extraordinary technique and expressive artistry, Lang Lang has brought classical music to audiences across cultures and generations. His dedication to mastery through discipline and refinement closely mirrors LOTUS's engineering philosophy, where every detail is shaped to deliver pure driving performance.

    2/6/26 8:30:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AZN
    $BLTE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/8/24 6:04:35 AM ET
    $LOT
    Auto Manufacturing
    Industrials